Earnings Call Summary | Alpha Teknova(TKNO.US) Q2 2024 Earnings Conference
Earnings Call Summary | Alpha Teknova(TKNO.US) Q2 2024 Earnings Conference
Adjusted EBITDA saw an improvement of $1.2 million compared to Q1 2024The following is a summary of the Alpha Teknova, Inc. (TKNO) Q2 2024 Earnings Call Transcript:
以下是Alpha Teknova，Inc.（TKNO）2024年第二季度業績會議調用摘要：
Financial Performance:
金融業績：
Teknova reported a decline in Q2 2024 revenue by 17% compared to the same quarter last year, resulting in total revenue of $9.6 million
Gross margin decreased to 29.2% due to lower Clinical Solutions revenue and higher overhead costs, notably from depreciation expense
Adjusted EBITDA saw an improvement of $1.2 million compared to Q1 2024
Net loss narrowed to $5.4 million, or $0.13 per diluted share
與去年同期相比，Teknova的Q2 2024年營業收入下降了17％，總收入爲960萬美元。
由於臨床解決方案收入較低，以及固定支出（尤其是折舊費用）增加，毛利率降至29.2％。
調整後的EBITDA與Q1 2024相比增加了120萬美元。
淨虧損收窄至540萬美元，每股攤薄後爲0.13美元。
Business Progress:
業務進展：
Introduced new manufacturing grade RUO+ and Express-Tek service to expedite production, aimed at generating high-margin revenue and addressing key customer pain points
Successfully increased clinical customers to 43, supporting the transition of therapies towards commercialization
推出新的製造級RUO+和Express-Tek服務，以加快生產，旨在產生高利潤收入，並解決關鍵客戶痛點。
成功將臨床客戶增加到43位，支持治療向商業化的轉型。
Opportunities:
機會：
With stabilization in biotech funding and a projected supportive market by 2025, Teknova anticipates leveraging increased engagement and new offerings to drive growth
Expects significant revenue uplift as clinical customers progress towards commercialization, particularly in cell & gene therapy segments
隨着生物技術資金穩定和2025年市場預期支持，Teknova預計利用更高的參與度和新的產品推動增長。
預計臨床客戶向商業化進展，特別是在細胞和基因治療領域，將帶來重大的營收提升。
More details: Alpha Teknova IR
更多詳情：Alpha Teknova IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
